Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 4/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL30361066 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL3343160 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29599595 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29363851 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL53998 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL30465862 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29588704 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29566149 | 1.00 | ADRA1A (1.00) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL1560198 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2315085 | 0.99 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 16724 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-20260115226-A1 | PHARMACEUTICAL COMPOSITION | MEDINCELL S.A. (FR) | 2026-04-30 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-4731194-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT | CSP Technologies, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4727545-A2 | COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS | Neurawell Therapeutics (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4719179-A2 | MANUFACTURING METHODS FOR GASTRIC RESIDENCE SYSTEMS | Nortiva Bio, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| US-12582601-B2 | Orodispersible powder composition | BIOPHARMA SYNERGIES, S.L. (ES) | 2026-03-24 | — | — | US | claimed |
| EP-4687805-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP Technologies, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| EP-4691462-A1 | SILYBIN-CONTAINING COMPOSITION | Tianjin Tasly Sants Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| US-20260027008-A1 | MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING ACTIVATED CARBON OR A DERIVATIVE THEREOF | CSP TECHNOLOGIES, INC. | 2026-01-29 | — | — | US | claimed |
| WO-1998037872-A2 | TRANSDERMAL DRUG DELIVERY SYSTEM FOR THE ADMINISTRATION OF TAMSULOSIN, AND RELATED COMPOSITIONS AND METHODS OF USE | CYGNUS, INC. (US) | 1998-09-03 | — | — | WO | claimed |
| WO-1998037870-A1 | TRANSDERMAL DELIVERY OF BASIC DRUGS USING NONPOLAR ADHESIVE SYSTEMS AND ACIDIC SOLUBILIZING AGENTS | CYGNUS, INC. (US) | 1998-09-03 | — | — | WO | claimed |
| EP-0833641-A1 | TREATMENT AND PREVENTION OF PROSTATIC DISEASE | Merck & Co., Inc. (US) | 1998-04-08 | — | — | EP | claimed |
| EP-0799619-A2 | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia | PFIZER INC. (US) | 1997-10-08 | — | — | EP | claimed |
| EP-0799618-A2 | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer | PFIZER INC. (US) | 1997-10-08 | — | — | EP | claimed |
| WO-1997027749-A1 | NITROSATED AND NITROSYLATED α-ADRENERGIC RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS AND THEIR USES | NITROMED, INC. (US) | 1997-08-07 | — | — | WO | claimed |
| WO-1996040150-A1 | TREATMENT AND PREVENTION OF PROSTATIC DISEASE | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0633781-A4 | COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY. | SMITHKLINE BEECHAM CORP (US) | 1995-04-19 | — | — | EP | claimed |
| EP-0633781-A1 | COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-18 | — | — | EP | claimed |
| WO-1993019758-A1 | COMPOSITIONS AND METHODS FOR TREATING BENIGN PROSTATIC HYPERTROPHY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-14 | — | — | WO | claimed |